Tandem Research Development from 2010 to 2026
| TNDM Stock | USD 20.66 0.77 3.87% |
Research Development | First Reported 2011-12-31 | Previous Quarter 48.1 M | Current Value 47.9 M | Quarterly Volatility 26.7 M |
Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem Diabetes' main balance sheet or income statement drivers, such as Depreciation And Amortization of 172.6 K, Interest Expense of 6.4 M or Selling General Administrative of 470.7 M, as well as many indicators such as Price To Sales Ratio of 2.74, Dividend Yield of 0.0 or PTB Ratio of 5.14. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
Tandem | Research Development | Build AI portfolio with Tandem Stock |
Evaluating Tandem Diabetes's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Tandem Diabetes Care's fundamental strength.
Latest Tandem Diabetes' Research Development Growth Pattern
Below is the plot of the Research Development of Tandem Diabetes Care over the last few years. It is Tandem Diabetes' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tandem Diabetes' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Tandem Research Development Regression Statistics
| Arithmetic Mean | 83,834,552 | |
| Geometric Mean | 40,921,945 | |
| Coefficient Of Variation | 110.69 | |
| Mean Deviation | 79,452,496 | |
| Median | 29,227,000 | |
| Standard Deviation | 92,797,764 | |
| Sample Variance | 8611.4T | |
| Range | 240.2M | |
| R-Value | 0.89 | |
| Mean Square Error | 1892.3T | |
| R-Squared | 0.79 | |
| Slope | 16,374,719 | |
| Total Sum of Squares | 137782.8T |
Tandem Research Development History
About Tandem Diabetes Financial Statements
Tandem Diabetes investors utilize fundamental indicators, such as Research Development, to predict how Tandem Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 228.7 M | 240.1 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Tandem Diabetes Correlation against competitors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Will Health Care Equipment & Supplies sector continue expanding? Could Tandem diversify its offerings? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Tandem Diabetes data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.37) | Earnings Share (3.03) | Revenue Per Share | Quarterly Revenue Growth 0.022 | Return On Assets |
Understanding Tandem Diabetes Care requires distinguishing between market price and book value, where the latter reflects Tandem's accounting equity. The concept of intrinsic value—what Tandem Diabetes' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Tandem Diabetes' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tandem Diabetes' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.